MedTrace Logo

A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma

NCT07100925 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-08-03

No results posted yet for this study

Summary

A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).

Conditions

  • Cutaneous Squamous Cell Carcinoma (CSCC)
  • Renal Transplant
  • Solid Tumor
  • Solid Tumor Cancer

Interventions

DRUG

tolododekin alfa

IT administration of ANK-101 once every 3 weeks for 2 cycles, followed by surgical resection

Sponsors & Collaborators

  • Ankyra Therapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • Joe Elassal, MD, MBA · Ankyra Therapeutics

  • Ann Silk, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2030-06-30
Completion
2030-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07100925 on ClinicalTrials.gov